Last reviewed · How we verify

Center for Human Reproduction — Portfolio Competitive Intelligence Brief

Center for Human Reproduction pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Human Growth Hormone Human Growth Hormone marketed Standardized Insect Venom Allergenic Extract [EPC]

Therapeutic area mix

No therapeutic area data.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Assiut University · 1 shared drug class
  2. Barbara Ann Karmanos Cancer Institute · 1 shared drug class
  3. Guna spa · 1 shared drug class
  4. Newton Laboratories, Inc. · 1 shared drug class
  5. Suez Canal University · 1 shared drug class
  6. Value Outcomes Ltd. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Center for Human Reproduction:

Cite this brief

Drug Landscape (2026). Center for Human Reproduction — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/center-for-human-reproduction. Accessed 2026-05-16.

Related